- Regulation of leukemic cell differentiation and retinoid-induced gene expression by statins
[作者:Sassano, A; Lo Lacono, M; Antico, G; Jordan, A; Uddin, S; Calogero, RA; Platanias, LC,期刊:Molecular Cancer Therapeutics, 页码:615-625 , 文章类型: Article,,卷期:2009年8-3]
- There is emerging evidence that, beyond their cholesterol-lowering properties, statins exhibit important antileukemic effects in vitro and in vivo, but the precise mechanisms by which they generate such responses remain ...
- LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer
[作者:Xie, H; Valera, VA; Merino, MJ; Amato, AM; Signoretti, S; Linehan, WM; Sukhatme, VP; Seth, P,期刊:Molecular Cancer Therapeutics, 页码:626-635 , 文章类型: Article,,卷期:2009年8-3]
- The genetic basis for the hereditary leiomyomatosis and renal cell cancer syndrome is germ-line inactivating mutation in the gene for the Krebs/tricarboxylic acid cycle enzyme, fumarate hydratase (FH), the enzyme that co...
- Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy
[作者:Yang, JM; Zaja-Milatovic, S; Thu, YM; Lee, F; Smykia, R; Richmond, A,期刊:Molecular Cancer Therapeutics, 页码:636-647 , 文章类型: Article,,卷期:2009年8-3]
- The BRAF(V600E) mutation is common in human melanoma. This mutation enhances I kappa B kinase (IKK)/nuclear factor-kappa B (NF-kappa B) and extracellular signal-regulated kinase/activator protein signaling cascades. In t...
- Efficacy of interleukin-13 receptor-targeted liposomal doxorubicin in the intracranial brain tumor model
[作者:Madhankumar, AB; Slagle-Webb, B; Wang, XS; Yang, QX; Antonetti, DA; Miller, PA; Sheehan, JM; Connor, JR,期刊:Molecular Cancer Therapeutics, 页码:648-654 , 文章类型: Article,,卷期:2009年8-3]
- Human glioblastoma tumors selectively express receptors for interleukin 13 (IL-13). In a previous study, we showed that liposomes, when conjugated with IL-13, will deliver chemotherapeutics to a subcutaneous glioma tumor...
- Cellular folate status modulates the expression of BCRP and MRP multidrug transporters in cancer cell lines from different origins
[作者:Lemos, C; Kathmann, L; Giovannetti, E; Belien, JAM; Scheffer, GL; Calhau, C; Jansen, G; Peters, GJ,期刊:Molecular Cancer Therapeutics, 页码:655-664 , 文章类型: Article,,卷期:2009年8-3]
- As cellular folate levels seem to have a different effect on cancer cells from different origins, we extended our initial study to a broader panel of cancer cells. BCRP and MRP1-5 expression was determined in KB, OVCAR-3...
- Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2
[作者:Feng, ST; Tang, GZ; Sun, M; Chun, JY; Evans, CP; Gao, AC,期刊:Molecular Cancer Therapeutics, 页码:665-671 , 文章类型: Article,,卷期:2009年8-3]
- The standard treatment for advanced, androgen-responsive prostate cancer is androgen deprivation therapy with or without a nonsteroidal antiandrogen, such as bicalutamide. Although maximal androgen blockade exhibits favo...
- In vivo molecular mediators of cancer growth suppression and apoptosis by selenium in mammary and prostate models: lack of involvement of gadd genes
[作者:Jiang, WQ; Jiang, C; Pei, HY; Wang, L; Zhang, JH; Hu, HB; Lu, JX,期刊:Molecular Cancer Therapeutics, 页码:682-691 , 文章类型: Article,,卷期:2009年8-3]
- We used acute selenium (Se) treatments (i.e., daily single oral gavage of 2 mg Se per kilogram of body weight for 3 days) of female Sprague-Dawley rats bearing 1-methyl-1-nitrosourea-induced mammary carcinomas to increas...
- Potent induction of B- and T-cell immunity against human carcinoembryonic antigen-expressing tumors in human carcinoembryonic antigen transgenic mice mediated by direct lentivector injection
[作者:Loisel-Meyer, S; Felizardo, T; Mariotti, J; Mossoba, ME; Foley, JE; Kammerer, R; Mizue, N; Keefe, R; McCart, JA; Zimmermann, W; Dropulic, B; Fowler, DH; Medin, JA,期刊:Molecular Cancer Therapeutics, 页码:692-702 , 文章类型: Article,,卷期:2009年8-3]
- The applicability of immunotherapy would be dramatically broadened to a greater number of recipients if direct "off-the-shelf" products could be engineered to engender functionally potent immune responses against true "s...
- Molecular imaging of Bcr-Abl phosphokinase in a xenograft model
[作者:Wu, JY; Yang, DJ; Angelo, LS; Im, SK; Kurzrock, R,期刊:Molecular Cancer Therapeutics, 页码:703-710 , 文章类型: Article,,卷期:2009年8-3]
- The purpose of this study was to determine whether the Bcr-Abl tyrosine kinase can be assessed by gamma-imaging using an In-111-labeled anti-phosphotyrosine (APT) antibody, and if the response to treatment with imatinib ...
- Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer
[作者:Schittenhelm, MM; Kollmannsberger, C; Oechsle, K; Harlow, A; Morich, J; Honecker, F; Kurek, R; Storkel, S; Kanz, L; Corless, CL; Wong, KK; Bokemeyer, C; Heinrich, MC,期刊:Molecular Cancer Therapeutics, 页码:481-489 , 文章类型: Article,,卷期:2009年8-3]
- Antibodies targeting epidermal growth factor receptor (EGFR) have proven to be effective in patients with non-small cell lung cancer (NSCLC) that express EGFR. We recently published a phase I study of weekly matuzumab pl...
- CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model
[作者:Ma, XR; Norsworthy, K; Kundu, N; Rodgers, WH; Gimotty, PA; Goloubeva, O; Lipsky, M; Li, Y; Holt, D; Fulton, A,期刊:Molecular Cancer Therapeutics, 页码:490-498 , 文章类型: Article,,卷期:2009年8-3]
- Breast tumor cells express the chemokine receptor CXCR3, which binds the ligands CXCL9, CXCL10, and CXCL11. CXCR3 and other chemokine receptors may mediate tumor metastasis by supporting migration of tumor cells to sites...
- Inhibition of vimentin or beta(1) integrin revert morphology of prostate tumor cells grown in laminin-rich extracellular matrix gels and reduces tumor growth in vivo
[作者:Zhang, XP; Fournier, MV; Ware, JL; Bissell, MJ; Yacoub, A; Zehner, ZE,期刊:Molecular Cancer Therapeutics, 页码:499-508 , 文章类型: Article,,卷期:2009年8-3]
- Prostate epithelial cells grown embedded in laminin-rich extracellular matrix (IrECM) undergo morphologic changes that closely resemble their architecture in vivo. In this study, growth characteristics of three human pro...
- Identification of a small molecule class to enhance cell-cell adhesion and attenuate prostate tumor growth and metastasis
[作者:Shah, GV; Muralidharan, A; Thomas, S; Gokulgandhi, M; Mudit, M; Khanfar, M; El Sayed, K,期刊:Molecular Cancer Therapeutics, 页码:509-520 , 文章类型: Article,,卷期:2009年8-3]
- Expression of calcitonin (CT) and its receptor (CTR) is elevated in advanced prostate cancer, and activated CT-CTR autocrine axis plays a pivotal role in tumorigenicity and metastatic potential of multiple prostate cance...
- Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells
[作者:Zinner, RG; Barrett, BL; Popova, E; Damien, P; Volgin, AY; Gelovani, JG; Lotan, R; Tran, HT; Pisano, C; Mills, GB; Mao, L; Hong, WK; Lippman, SM; Miller, JH,期刊:Molecular Cancer Therapeutics, 页码:521-532 , 文章类型: Article,,卷期:2009年8-3]
- The standard treatment for most advanced cancers is multidrug therapy. Unfortunately, combinations in the clinic often do not perform as predicted. Therefore, to complement identifying rational drug combinations based on...
- Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression
[作者:Konduri, S; Colon, J; Baker, CH; Safe, S; Abbruzzese, JL; Abudayyeh, A; Basha, MR; Abdelrahim, M,期刊:Molecular Cancer Therapeutics, 页码:533-542 , 文章类型: Article,,卷期:2009年8-3]
- Survivin is overexpressed in most human cancers, including pancreatic adenocarcinoma. Expression of survivin is regulated by specificity protein (Sp) proteins and related to resistance to radiation therapy. Tolfenamic ac...
|